Governance & Derivative
Kyverna Therapeutics, Inc. (NasdaqGS: KYTX)
Contact a Lawyer Now
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NasdaqGS: KYTX).
According to a securities lawsuit filed against the Company, the registration statement and prospectus Kyverna used to conduct its initial public offering on February 8, 2024 (the “IPO”) misstated and/or omitted material facts about the results of the Company’s ongoing clinical evaluation of KYV-101, its lead product candidate. Specifically, the lawsuit alleges that Kyverna touted patient “improvement” in certain indicators while failing to disclose adverse data from one of its clinical trials, even though that data was known to the Company at the time of the IPO. As a result, investors allegedly purchased Kyverna shares at artificially inflated prices. When the true details entered the market, the lawsuit claims, investors suffered damages.
KSF’s investigation is focusing on whether Kyverna’s officers and/or directors of breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Kyverna’s shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at (833) 538-3606 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or fill out the form on this page.